Kailera Therapeutics, Inc. (KLRA)
NASDAQ:KLRA
Want to see KLRA full AI Analyst Report?
KLRA Stock Chart & Stats
$24.76
$0.94(3.95%)
―
--
Day’s Range― - ―
52-Week Range$20.87 - $28.23
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding129,537,310
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kailera Therapeutics, Inc. News
KLRA FAQ
What was Kailera Therapeutics, Inc.’s price range in the past 12 months?
Kailera Therapeutics, Inc. lowest stock price was $20.86 and its highest was $28.23 in the past 12 months.
What is Kailera Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Kailera Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kailera Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Kailera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kailera Therapeutics, Inc.’s price is currently Undervalued.
Does Kailera Therapeutics, Inc. pay dividends?
Kailera Therapeutics, Inc. does not currently pay dividends.
What is Kailera Therapeutics, Inc.’s EPS estimate?
Kailera Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kailera Therapeutics, Inc. have?
Kailera Therapeutics, Inc. has 129,537,310 shares outstanding.
What happened to Kailera Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kailera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KLRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kailera Therapeutics, Inc.
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. The company emphasizes innovative approaches, including injectable and oral formulations, to support chronic weight management. [2] Its lead program is a dual-action gut hormone receptor agonist that has demonstrated promising clinical results in early trials.
Ownership Overview
Options Prices
Currently, No data available
---